To report an analysis of adherence, results from a patient satisfaction questionnaire, and correlations between in-clinic tests and FLOODLIGHT (NCT02952911) measures.

Sensor-based, active and passive self-monitoring may be more sensitive and specific than periodic in-clinic assessments to measure progression in multiple sclerosis (MS).

Patients with MS (20–57 years; Expanded Disability Status Scale score 0–5.5; n=76) and healthy controls (n=25) received a preconfigured smartphone and smartwatch that prompts the user to perform the FLOODLIGHT test battery, comprising ‘active tests’ and ‘passive monitoring’, for 24 weeks. The primary analysis assessed participants’ adherence (proportion of study weeks with at least 3 days of completed active testing and at least 4 hours/day of passive monitoring) and patient satisfaction with the FLOODLIGHT monitoring solution. In-clinic tests and brain MRI assessments were performed. Secondary analyses explored whether FLOODLIGHT sensor-based outcomes 1) differed between patients with MS and healthy controls and 2) correlated with in-clinic outcomes. The correlation between FLOODLIGHT sensor-based outcomes and in-clinic tests was reported using Spearman’s correlation coefficient (SCC).

The analysis of adherence of patients who completed the study showed 69.5% adherence to active tests and 78.7% to passive monitoring. Satisfaction among patients with MS who completed the study (n=68) was good-to-excellent (72.7 average score out of a possible 100 at termination visit). Correlation between the Turning speed measured with the FLOODLIGHT Five-U-Turn Test vs Timed 25-Foot Walk test time was SCC=–0.501 (p<0.001, n=60). Further comparisons between baseline FLOODLIGHT sensor-based and in-clinic testing MS outcomes will be presented.

Patients’ adherence and satisfaction combined with correlations observed between clinical and sensor-based outcomes show promising potential for the FLOODLIGHT monitoring solution to capture meaningfully relevant outcomes augmenting the clinical picture in patients with MS.